1 - Concerning new drugs that enhance the dopaminergic transmission in brain:
A- They can be used as antipsychotics.
B- They can increase prolactin secretion as a side effect.
C- They can be used in treatment of parkinsonism.
D- Both A & C.
E- None of the above.
2 - Concerning new drugs that increase the levels of nor-epinephrine in brain:
A- They can be used as antipsychotics.
B- They can be used in treatment of depression.
C- They may cause behavioral arousal and alertness.
D- Both B & C.
E- All of the above.
3 - Concerning new drugs that block cholinergic receptors in brain:
A- They can be used in treatment of Alzeheimer’s disease.
B- They may impair memory.
C- They may used in treatment of parkinson’s disease.
D- Both B & C.
E- All of the above.
4- Concerning GABA receptors:
A- Muscimol is a selective GABAB receptor agonist.
B- Activation of GABAA receptors is associated with hyperpolarization due to
opening of chloride channels.
C- Barbituraes potentiate the action of GABAB receptors.
D- Both A & B.
E- None of the above.
5 - Concerning the use of new drugs that found to increase serotonin levels in brain:
A- They can be used in treatment of depression.
B- They are effective as antipsychotics.
C- they may have anticonvulsant activity.
D- Both A & B.
E- All of the above.
6 – Which of the following mechanisms may explain the mode of action of
antiepileptic drugs:
A- Blocking GABA receptors.
B- Inhibition of metabolism of GABA.
C- Blocking glutamate (NMDA) receptors.
D- Both B & C.
E- All of the above.
7 - Concerning the expected side effects of centrally-acting new drugs:
A- Drowsiness & muscle relaxation for drugs that enhance GABA action.
B- Convulsions for drugs that block glutamate receptors.
C- Hallucination & aggressive behavior for drugs that enhance GABA action.
D- All of the above.
E- None of the above.
8- Which of the following mechanisms may explain the effectiveness of new drugs
that developed to treat depression?
A- Inhibition of MAO enzyme.
B- Inhibition of GABA-t enzyme.
C- Inhibition of NE & 5-HT reuptake into central neurons.
D- Both A & C.
E- All of the above.
9- Concerning glycine neurotransmitter:
A- Strychnine produces its convulsant effect by blocking GABA receptors.
B- NMDA receptors are activated by glycine neurotransmitter.
C- Drugs that block glycine receptors can be used as antiepileptics.
D- Both A & C.
E- None of the above.
10- Concerning GABA receptors:
A- Baclofen is a GABAA receptor agonist.
B- Bicuculine is a non-competitive GABAA receptor antagonist.
C- Benzodiazepines are GABAA receptor agonist.
D- Both A & C.
E- None of the above.
T F 1- Loss of dopaminergic neurons in basal ganglia may cause schizophrenia.
T F 2- Drugs that increase central cholinergic transmission can be used to treat
Alzheimer disease.
T F 3- Drugs that block GABA reuptake into neurons can be used in treatment of
epilepsy.
T F 4- Selective serotonin reuptake inhibitors can be used in treatment of Parkinson’s
disease.
T F 5- Drugs that inhibit norepinephrine metabolism can be used in treatment of
depression.
T F 6- GABA agonists may cause convulsion as a side effect.
T F 7- Anticonvulsant drugs may act by potentiating GABA action.
T F 8- Dopamine antagonists may produce hallucination as a side effect.
T F 9- 5-HT1A receptor agonists can be used to treat insomnia.
T F 10- Drugs that block GABA can be used in treatment of anxiety.